QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
ASX:NEU

Neuren Pharmaceuticals Limited (NEU.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$1.72
MA: A$1.72
A$1.72
52-Week Range N/A
Volume57,935 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9092 0480
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$545,000.00
Book ValueA$0.09 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive NEU News and Ratings via Email

Sign-up to receive the latest news and ratings for NEU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neuren Pharmaceuticals Limited (NEU.AX) (ASX:NEU) Frequently Asked Questions

What stocks does MarketBeat like better than Neuren Pharmaceuticals Limited (NEU.AX)?

Wall Street analysts have given Neuren Pharmaceuticals Limited (NEU.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neuren Pharmaceuticals Limited (NEU.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Neuren Pharmaceuticals Limited (NEU.AX)'s earnings last quarter?

Neuren Pharmaceuticals Limited (NEU.AX) (ASX:NEU) posted its earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter.
View Neuren Pharmaceuticals Limited (NEU.AX)'s earnings history
.

Who are some of Neuren Pharmaceuticals Limited (NEU.AX)'s key competitors?

What other stocks do shareholders of Neuren Pharmaceuticals Limited (NEU.AX) own?

Who are Neuren Pharmaceuticals Limited (NEU.AX)'s key executives?

Neuren Pharmaceuticals Limited (NEU.AX)'s management team includes the following people:
  • Mr. Lawrence Glass, Chief Science Officer
  • Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA, Chief Exec. Officer
  • Ms. Lauren Frazer C.A., CFO & Company Sec.

What is Neuren Pharmaceuticals Limited (NEU.AX)'s stock symbol?

Neuren Pharmaceuticals Limited (NEU.AX) trades on the ASX under the ticker symbol "NEU."

How big of a company is Neuren Pharmaceuticals Limited (NEU.AX)?

Neuren Pharmaceuticals Limited (NEU.AX) has a market capitalization of $0.00 and generates $545,000.00 in revenue each year. Neuren Pharmaceuticals Limited (NEU.AX) employs 8 workers across the globe.

What is Neuren Pharmaceuticals Limited (NEU.AX)'s official website?

The official website for Neuren Pharmaceuticals Limited (NEU.AX) is www.neurenpharma.com.

How can I contact Neuren Pharmaceuticals Limited (NEU.AX)?

The company can be reached via phone at 61 3 9092 0480.

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.